Korean biotech IPO gives STIC 2x exit
The Seoul-based private equity and secondaries fund manager has exited its investment in Medy-Tox, generating a net IRR of 33.2% in two years.
5 January 2013•1 min read
The Seoul-based private equity and secondaries fund manager has exited its investment in Medy-Tox, generating a net IRR of 33.2% in two years.
